TargetHistone acetyltransferase KAT6A [507-778](Homo sapiens)
Cancer Therapeutics Crc
Curated by ChEMBL
Cancer Therapeutics Crc
Curated by ChEMBL
Affinity DataIC50: 2nMAssay Description:Inhibition of N-terminal NusA-fused His6-tagged human KAT6A (507 to 778 residues) expressed in Escherichia coli BL21 (DE3) cells using 0.4 uM acetyl ...More data for this Ligand-Target Pair
TargetHistone acetyltransferase KAT6A [507-778](Homo sapiens)
Cancer Therapeutics Crc
Curated by ChEMBL
Cancer Therapeutics Crc
Curated by ChEMBL
Affinity DataIC50: 5nMAssay Description:Inhibition of N-terminal NusA-fused His6-tagged human KAT6A (507 to 778 residues) expressed in Escherichia coli BL21 (DE3) cells using 0.4 uM acetyl ...More data for this Ligand-Target Pair
TargetHistone acetyltransferase KAT6A [507-778](Homo sapiens)
Cancer Therapeutics Crc
Curated by ChEMBL
Cancer Therapeutics Crc
Curated by ChEMBL
Affinity DataIC50: 5.5nMAssay Description:Inhibition of N-terminal NusA-fused His6-tagged human KAT6A (507 to 778 residues) expressed in Escherichia coli BL21 (DE3) cells using 0.4 uM acetyl ...More data for this Ligand-Target Pair
TargetHistone acetyltransferase KAT6A [507-778](Homo sapiens)
Cancer Therapeutics Crc
Curated by ChEMBL
Cancer Therapeutics Crc
Curated by ChEMBL
Affinity DataIC50: 6nMAssay Description:Inhibition of N-terminal NusA-fused His6-tagged human KAT6A (507 to 778 residues) expressed in Escherichia coli BL21 (DE3) cells using 0.4 uM acetyl ...More data for this Ligand-Target Pair
TargetHistone acetyltransferase KAT6A [507-778](Homo sapiens)
Cancer Therapeutics Crc
Curated by ChEMBL
Cancer Therapeutics Crc
Curated by ChEMBL
Affinity DataIC50: 6.30nMAssay Description:Inhibition of N-terminal NusA-fused His6-tagged human KAT6A (507 to 778 residues) expressed in Escherichia coli BL21 (DE3) cells using 0.4 uM acetyl ...More data for this Ligand-Target Pair
TargetHistone acetyltransferase KAT6A [507-778](Homo sapiens)
Cancer Therapeutics Crc
Curated by ChEMBL
Cancer Therapeutics Crc
Curated by ChEMBL
Affinity DataIC50: 7nMAssay Description:Inhibition of N-terminal NusA-fused His6-tagged human KAT6A (507 to 778 residues) expressed in Escherichia coli BL21 (DE3) cells using 0.4 uM acetyl ...More data for this Ligand-Target Pair
TargetHistone acetyltransferase KAT6A [507-778](Homo sapiens)
Cancer Therapeutics Crc
Curated by ChEMBL
Cancer Therapeutics Crc
Curated by ChEMBL
Affinity DataIC50: 8nMAssay Description:Active Moz protein was expressed as N-terminal fusion protein with a His6 tag in BL21 E. coli cells. Protein purification was performed via nickel-im...More data for this Ligand-Target Pair
TargetHistone acetyltransferase KAT6A [507-778](Homo sapiens)
Cancer Therapeutics Crc
Curated by ChEMBL
Cancer Therapeutics Crc
Curated by ChEMBL
Affinity DataIC50: 8nMAssay Description:Inhibition of N-terminal NusA-fused His6-tagged human KAT6A (507 to 778 residues) expressed in Escherichia coli BL21 (DE3) cells using 0.4 uM acetyl ...More data for this Ligand-Target Pair
TargetHistone acetyltransferase KAT6A [507-778](Homo sapiens)
Cancer Therapeutics Crc
Curated by ChEMBL
Cancer Therapeutics Crc
Curated by ChEMBL
Affinity DataIC50: 8nMAssay Description:Inhibition of N-terminal NusA-fused His6-tagged human KAT6A (507 to 778 residues) expressed in Escherichia coli BL21 (DE3) cells using 0.4 uM acetyl ...More data for this Ligand-Target Pair
TargetHistone acetyltransferase KAT6A [507-778](Homo sapiens)
Cancer Therapeutics Crc
Curated by ChEMBL
Cancer Therapeutics Crc
Curated by ChEMBL
Affinity DataIC50: 9nMAssay Description:Inhibition of N-terminal NusA-fused His6-tagged human KAT6A (507 to 778 residues) expressed in Escherichia coli BL21 (DE3) cells using 0.4 uM acetyl ...More data for this Ligand-Target Pair
TargetHistone acetyltransferase KAT6A [507-778](Homo sapiens)
Cancer Therapeutics Crc
Curated by ChEMBL
Cancer Therapeutics Crc
Curated by ChEMBL
Affinity DataIC50: 9nMAssay Description:Inhibition of N-terminal NusA-fused His6-tagged human KAT6A (507 to 778 residues) expressed in Escherichia coli BL21 (DE3) cells using 0.4 uM acetyl ...More data for this Ligand-Target Pair
TargetHistone acetyltransferase KAT6A [507-778](Homo sapiens)
Cancer Therapeutics Crc
Curated by ChEMBL
Cancer Therapeutics Crc
Curated by ChEMBL
Affinity DataIC50: 9.40nMAssay Description:Inhibition of N-terminal NusA-fused His6-tagged human KAT6A (507 to 778 residues) expressed in Escherichia coli BL21 (DE3) cells using 0.4 uM acetyl ...More data for this Ligand-Target Pair
TargetHistone acetyltransferase KAT6A [507-778](Homo sapiens)
Cancer Therapeutics Crc
Curated by ChEMBL
Cancer Therapeutics Crc
Curated by ChEMBL
Affinity DataIC50: 10nMAssay Description:Active Moz protein was expressed as N-terminal fusion protein with a His6 tag in BL21 E. coli cells. Protein purification was performed via nickel-im...More data for this Ligand-Target Pair
TargetHistone acetyltransferase KAT6A [507-778](Homo sapiens)
Cancer Therapeutics Crc
Curated by ChEMBL
Cancer Therapeutics Crc
Curated by ChEMBL
Affinity DataIC50: 10nMAssay Description:Active Moz protein was expressed as N-terminal fusion protein with a His6 tag in BL21 E. coli cells. Protein purification was performed via nickel-im...More data for this Ligand-Target Pair
TargetHistone acetyltransferase KAT6A [507-778](Homo sapiens)
Cancer Therapeutics Crc
Curated by ChEMBL
Cancer Therapeutics Crc
Curated by ChEMBL
Affinity DataIC50: 10nMAssay Description:Inhibition of N-terminal NusA-fused His6-tagged human KAT6A (507 to 778 residues) expressed in Escherichia coli BL21 (DE3) cells using 0.4 uM acetyl ...More data for this Ligand-Target Pair
TargetHistone acetyltransferase KAT6A [507-778](Homo sapiens)
Cancer Therapeutics Crc
Curated by ChEMBL
Cancer Therapeutics Crc
Curated by ChEMBL
Affinity DataIC50: 11nMAssay Description:Inhibition of N-terminal NusA-fused His6-tagged human KAT6A (507 to 778 residues) expressed in Escherichia coli BL21 (DE3) cells using 0.4 uM acetyl ...More data for this Ligand-Target Pair
TargetHistone acetyltransferase KAT6A [507-778](Homo sapiens)
Cancer Therapeutics Crc
Curated by ChEMBL
Cancer Therapeutics Crc
Curated by ChEMBL
Affinity DataIC50: 13nMAssay Description:Inhibition of N-terminal NusA-fused His6-tagged human KAT6A (507 to 778 residues) expressed in Escherichia coli BL21 (DE3) cells using 0.4 uM acetyl ...More data for this Ligand-Target Pair
TargetHistone acetyltransferase KAT6A [507-778](Homo sapiens)
Cancer Therapeutics Crc
Curated by ChEMBL
Cancer Therapeutics Crc
Curated by ChEMBL
Affinity DataIC50: 13nMAssay Description:Inhibition of N-terminal NusA-fused His6-tagged human KAT6A (507 to 778 residues) expressed in Escherichia coli BL21 (DE3) cells using 0.4 uM acetyl ...More data for this Ligand-Target Pair
TargetHistone acetyltransferase KAT6A [507-778](Homo sapiens)
Cancer Therapeutics Crc
Curated by ChEMBL
Cancer Therapeutics Crc
Curated by ChEMBL
Affinity DataIC50: 14nMAssay Description:Inhibition of N-terminal NusA-fused His6-tagged human KAT6A (507 to 778 residues) expressed in Escherichia coli BL21 (DE3) cells using 0.4 uM acetyl ...More data for this Ligand-Target Pair
TargetHistone acetyltransferase KAT6A [507-778](Homo sapiens)
Cancer Therapeutics Crc
Curated by ChEMBL
Cancer Therapeutics Crc
Curated by ChEMBL
Affinity DataIC50: 14nMAssay Description:Inhibition of N-terminal NusA-fused His6-tagged human KAT6A (507 to 778 residues) expressed in Escherichia coli BL21 (DE3) cells using 0.4 uM acetyl ...More data for this Ligand-Target Pair
TargetHistone acetyltransferase KAT6A [507-778](Homo sapiens)
Cancer Therapeutics Crc
Curated by ChEMBL
Cancer Therapeutics Crc
Curated by ChEMBL
Affinity DataIC50: 14nMAssay Description:Inhibition of N-terminal NusA-fused His6-tagged human KAT6A (507 to 778 residues) expressed in Escherichia coli BL21 (DE3) cells using 0.4 uM acetyl ...More data for this Ligand-Target Pair
TargetHistone acetyltransferase KAT6A [507-778](Homo sapiens)
Cancer Therapeutics Crc
Curated by ChEMBL
Cancer Therapeutics Crc
Curated by ChEMBL
Affinity DataIC50: 15nMAssay Description:Inhibition of N-terminal NusA-fused His6-tagged human KAT6A (507 to 778 residues) expressed in Escherichia coli BL21 (DE3) cells using 0.4 uM acetyl ...More data for this Ligand-Target Pair
TargetHistone acetyltransferase KAT6A [507-778](Homo sapiens)
Cancer Therapeutics Crc
Curated by ChEMBL
Cancer Therapeutics Crc
Curated by ChEMBL
Affinity DataIC50: 16nMAssay Description:Inhibition of N-terminal NusA-fused His6-tagged human KAT6A (507 to 778 residues) expressed in Escherichia coli BL21 (DE3) cells using 0.4 uM acetyl ...More data for this Ligand-Target Pair
TargetHistone acetyltransferase KAT6A [507-778](Homo sapiens)
Cancer Therapeutics Crc
Curated by ChEMBL
Cancer Therapeutics Crc
Curated by ChEMBL
Affinity DataIC50: 16nMAssay Description:Inhibition of N-terminal NusA-fused His6-tagged human KAT6A (507 to 778 residues) expressed in Escherichia coli BL21 (DE3) cells using 0.4 uM acetyl ...More data for this Ligand-Target Pair
TargetHistone acetyltransferase KAT6A [507-778](Homo sapiens)
Cancer Therapeutics Crc
Curated by ChEMBL
Cancer Therapeutics Crc
Curated by ChEMBL
Affinity DataIC50: 17nMAssay Description:Inhibition of N-terminal NusA-fused His6-tagged human KAT6A (507 to 778 residues) expressed in Escherichia coli BL21 (DE3) cells using 0.4 uM acetyl ...More data for this Ligand-Target Pair
TargetHistone acetyltransferase KAT6A [507-778](Homo sapiens)
Cancer Therapeutics Crc
Curated by ChEMBL
Cancer Therapeutics Crc
Curated by ChEMBL
Affinity DataIC50: 17nMAssay Description:Inhibition of N-terminal NusA-fused His6-tagged human KAT6A (507 to 778 residues) expressed in Escherichia coli BL21 (DE3) cells using 0.4 uM acetyl ...More data for this Ligand-Target Pair
TargetHistone acetyltransferase KAT6A [507-778](Homo sapiens)
Cancer Therapeutics Crc
Curated by ChEMBL
Cancer Therapeutics Crc
Curated by ChEMBL
Affinity DataIC50: 17nMAssay Description:Inhibition of N-terminal NusA-fused His6-tagged human KAT6A (507 to 778 residues) expressed in Escherichia coli BL21 (DE3) cells using 0.4 uM acetyl ...More data for this Ligand-Target Pair
TargetHistone acetyltransferase KAT6A [507-778](Homo sapiens)
Cancer Therapeutics Crc
Curated by ChEMBL
Cancer Therapeutics Crc
Curated by ChEMBL
Affinity DataIC50: 17nMAssay Description:Active Moz protein was expressed as N-terminal fusion protein with a His6 tag in BL21 E. coli cells. Protein purification was performed via nickel-im...More data for this Ligand-Target Pair
TargetHistone acetyltransferase KAT6A [507-778](Homo sapiens)
Cancer Therapeutics Crc
Curated by ChEMBL
Cancer Therapeutics Crc
Curated by ChEMBL
Affinity DataIC50: 18nMAssay Description:Inhibition of N-terminal NusA-fused His6-tagged human KAT6A (507 to 778 residues) expressed in Escherichia coli BL21 (DE3) cells using 0.4 uM acetyl ...More data for this Ligand-Target Pair
TargetHistone acetyltransferase KAT6A [507-778](Homo sapiens)
Cancer Therapeutics Crc
Curated by ChEMBL
Cancer Therapeutics Crc
Curated by ChEMBL
Affinity DataIC50: 18nMAssay Description:Inhibition of N-terminal NusA-fused His6-tagged human KAT6A (507 to 778 residues) expressed in Escherichia coli BL21 (DE3) cells using 0.4 uM acetyl ...More data for this Ligand-Target Pair
TargetHistone acetyltransferase KAT6A [507-778](Homo sapiens)
Cancer Therapeutics Crc
Curated by ChEMBL
Cancer Therapeutics Crc
Curated by ChEMBL
Affinity DataIC50: 20nMAssay Description:Inhibition of N-terminal NusA-fused His6-tagged human KAT6A (507 to 778 residues) expressed in Escherichia coli BL21 (DE3) cells using 0.4 uM acetyl ...More data for this Ligand-Target Pair
TargetHistone acetyltransferase KAT6A [507-778](Homo sapiens)
Cancer Therapeutics Crc
Curated by ChEMBL
Cancer Therapeutics Crc
Curated by ChEMBL
Affinity DataIC50: 20nMAssay Description:Inhibition of N-terminal NusA-fused His6-tagged human KAT6A (507 to 778 residues) expressed in Escherichia coli BL21 (DE3) cells using 0.4 uM acetyl ...More data for this Ligand-Target Pair
TargetHistone acetyltransferase KAT6A [507-778](Homo sapiens)
Cancer Therapeutics Crc
Curated by ChEMBL
Cancer Therapeutics Crc
Curated by ChEMBL
Affinity DataIC50: 23nMAssay Description:Inhibition of N-terminal NusA-fused His6-tagged human KAT6A (507 to 778 residues) expressed in Escherichia coli BL21 (DE3) cells using 0.4 uM acetyl ...More data for this Ligand-Target Pair
TargetHistone acetyltransferase KAT6A [507-778](Homo sapiens)
Cancer Therapeutics Crc
Curated by ChEMBL
Cancer Therapeutics Crc
Curated by ChEMBL
Affinity DataIC50: 23nMAssay Description:Inhibition of N-terminal NusA-fused His6-tagged human KAT6A (507 to 778 residues) expressed in Escherichia coli BL21 (DE3) cells using 0.4 uM acetyl ...More data for this Ligand-Target Pair
TargetHistone acetyltransferase KAT6A [507-778](Homo sapiens)
Cancer Therapeutics Crc
Curated by ChEMBL
Cancer Therapeutics Crc
Curated by ChEMBL
Affinity DataIC50: 24nMAssay Description:Inhibition of N-terminal NusA-fused His6-tagged human KAT6A (507 to 778 residues) expressed in Escherichia coli BL21 (DE3) cells using 0.4 uM acetyl ...More data for this Ligand-Target Pair
TargetHistone acetyltransferase KAT6A [507-778](Homo sapiens)
Cancer Therapeutics Crc
Curated by ChEMBL
Cancer Therapeutics Crc
Curated by ChEMBL
Affinity DataIC50: 24nMAssay Description:Inhibition of N-terminal NusA-fused His6-tagged human KAT6A (507 to 778 residues) expressed in Escherichia coli BL21 (DE3) cells using 0.4 uM acetyl ...More data for this Ligand-Target Pair
TargetHistone acetyltransferase KAT6A [507-778](Homo sapiens)
Cancer Therapeutics Crc
Curated by ChEMBL
Cancer Therapeutics Crc
Curated by ChEMBL
Affinity DataIC50: 24nMAssay Description:Inhibition of N-terminal NusA-fused His6-tagged human KAT6A (507 to 778 residues) expressed in Escherichia coli BL21 (DE3) cells using 0.4 uM acetyl ...More data for this Ligand-Target Pair
TargetHistone acetyltransferase KAT6A [507-778](Homo sapiens)
Cancer Therapeutics Crc
Curated by ChEMBL
Cancer Therapeutics Crc
Curated by ChEMBL
Affinity DataIC50: 25nMAssay Description:Inhibition of N-terminal NusA-fused His6-tagged human KAT6A (507 to 778 residues) expressed in Escherichia coli BL21 (DE3) cells using 0.4 uM acetyl ...More data for this Ligand-Target Pair
TargetHistone acetyltransferase KAT6A [507-778](Homo sapiens)
Cancer Therapeutics Crc
Curated by ChEMBL
Cancer Therapeutics Crc
Curated by ChEMBL
Affinity DataIC50: 26nMAssay Description:Inhibition of N-terminal NusA-fused His6-tagged human KAT6A (507 to 778 residues) expressed in Escherichia coli BL21 (DE3) cells using 0.4 uM acetyl ...More data for this Ligand-Target Pair
TargetHistone acetyltransferase KAT6A [507-778](Homo sapiens)
Cancer Therapeutics Crc
Curated by ChEMBL
Cancer Therapeutics Crc
Curated by ChEMBL
Affinity DataIC50: 27nMAssay Description:Inhibition of N-terminal NusA-fused His6-tagged human KAT6A (507 to 778 residues) expressed in Escherichia coli BL21 (DE3) cells using 0.4 uM acetyl ...More data for this Ligand-Target Pair
TargetHistone acetyltransferase KAT6A [507-778](Homo sapiens)
Cancer Therapeutics Crc
Curated by ChEMBL
Cancer Therapeutics Crc
Curated by ChEMBL
Affinity DataIC50: 27nMAssay Description:Inhibition of N-terminal NusA-fused His6-tagged human KAT6A (507 to 778 residues) expressed in Escherichia coli BL21 (DE3) cells using 0.4 uM acetyl ...More data for this Ligand-Target Pair
Affinity DataIC50: 28nMAssay Description:Inhibition of N-terminal GST-tagged recombinant human KAT6B (431 to end residues) expressed in baculovirus infected Sf9 insect cells using acetyl coe...More data for this Ligand-Target Pair
TargetHistone acetyltransferase KAT6A [507-778](Homo sapiens)
Cancer Therapeutics Crc
Curated by ChEMBL
Cancer Therapeutics Crc
Curated by ChEMBL
Affinity DataIC50: 29nMAssay Description:Inhibition of N-terminal NusA-fused His6-tagged human KAT6A (507 to 778 residues) expressed in Escherichia coli BL21 (DE3) cells using 0.4 uM acetyl ...More data for this Ligand-Target Pair
TargetHistone acetyltransferase KAT6A [507-778](Homo sapiens)
Cancer Therapeutics Crc
Curated by ChEMBL
Cancer Therapeutics Crc
Curated by ChEMBL
Affinity DataIC50: 29nMAssay Description:Inhibition of N-terminal NusA-fused His6-tagged human KAT6A (507 to 778 residues) expressed in Escherichia coli BL21 (DE3) cells using 0.4 uM acetyl ...More data for this Ligand-Target Pair
TargetHistone acetyltransferase KAT6A [507-778](Homo sapiens)
Cancer Therapeutics Crc
Curated by ChEMBL
Cancer Therapeutics Crc
Curated by ChEMBL
Affinity DataIC50: 30nMAssay Description:Inhibition of N-terminal NusA-fused His6-tagged human KAT6A (507 to 778 residues) expressed in Escherichia coli BL21 (DE3) cells using 0.4 uM acetyl ...More data for this Ligand-Target Pair
TargetHistone acetyltransferase KAT6A [507-778](Homo sapiens)
Cancer Therapeutics Crc
Curated by ChEMBL
Cancer Therapeutics Crc
Curated by ChEMBL
Affinity DataIC50: 31nMAssay Description:Inhibition of N-terminal NusA-fused His6-tagged human KAT6A (507 to 778 residues) expressed in Escherichia coli BL21 (DE3) cells using 0.4 uM acetyl ...More data for this Ligand-Target Pair
TargetHistone acetyltransferase KAT6A [507-778](Homo sapiens)
Cancer Therapeutics Crc
Curated by ChEMBL
Cancer Therapeutics Crc
Curated by ChEMBL
Affinity DataIC50: 32nMAssay Description:Inhibition of N-terminal NusA-fused His6-tagged human KAT6A (507 to 778 residues) expressed in Escherichia coli BL21 (DE3) cells using 0.4 uM acetyl ...More data for this Ligand-Target Pair
TargetHistone acetyltransferase KAT6A [507-778](Homo sapiens)
Cancer Therapeutics Crc
Curated by ChEMBL
Cancer Therapeutics Crc
Curated by ChEMBL
Affinity DataIC50: 38nMAssay Description:Inhibition of N-terminal NusA-fused His6-tagged human KAT6A (507 to 778 residues) expressed in Escherichia coli BL21 (DE3) cells using 0.4 uM acetyl ...More data for this Ligand-Target Pair
TargetHistone acetyltransferase KAT6A [507-778](Homo sapiens)
Cancer Therapeutics Crc
Curated by ChEMBL
Cancer Therapeutics Crc
Curated by ChEMBL
Affinity DataIC50: 41nMAssay Description:Active Moz protein was expressed as N-terminal fusion protein with a His6 tag in BL21 E. coli cells. Protein purification was performed via nickel-im...More data for this Ligand-Target Pair
TargetHistone acetyltransferase KAT6A [507-778](Homo sapiens)
Cancer Therapeutics Crc
Curated by ChEMBL
Cancer Therapeutics Crc
Curated by ChEMBL
Affinity DataIC50: 43nMAssay Description:Inhibition of N-terminal NusA-fused His6-tagged human KAT6A (507 to 778 residues) expressed in Escherichia coli BL21 (DE3) cells using 0.4 uM acetyl ...More data for this Ligand-Target Pair